Loading clinical trials...
Loading clinical trials...
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
89bio, Inc.
NCT03587831 · NASH - Nonalcoholic Steatohepatitis
NCT04697810 · NASH - Nonalcoholic Steatohepatitis
NCT04383951 · NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
NCT02581085 · End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, and more
NCT03997422 · NASH - Nonalcoholic Steatohepatitis, NAS, and more
89bio Clinical Study Site
Birmingham, Alabama
89bio Clinical Study Site
Birmingham, Alabama
89bio Clinical Study Site
Dothan, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions